Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According to GlobalData, Phase II drugs for Splenic Marginal Zone B-Cell Lymphoma have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rituximab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rituximab biosimilar overview
Rituximab (Hanlikangt, Rituximab Biosimilar) is a monoclonal antibody acts as an anti neoplastic agent. It is formulated as injectable solution for intravenous route of administration. Hanlikang is indicated for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, diffuse Large B-cell non-Hodgkin’s lymphoma, relapsed or refractory follicular lymphoma and it is in combination with methotrexate indicated for the treatment of moderately-to severely-active rheumatoid Arthritis (RA) in adult patients with who have inadequate response to one or more TNF-alpha antagonist therapies.
Rituximab biosimilar (HLX-01) is under development idiopathic membranous nephropathy (iMN), follicular lymphoma, Extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue or MALT-Lymphoma), splenic marginal zone B-cell lymphoma. The drug candidate is administered as intravenous injection. It was also under development for follicular lymphoma and rheumatoid Arthritis (RA).
Shanghai Henlius Biotech overview
Shanghai Henlius Biotech (Henlius), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, is a biopharmaceutical company that develops medicine for oncology, autoimmune and ophthalmic diseases. It offers HANLIKANG, a rituximab injection, which treats non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HERCESSI, trastuzumab for injection for breast, metastatic breast and metastatic gastric cancer; Handayuan, Adalimumab injection, which targets rheumatoid arthritis, Ankylosing spondylitis, Psoriasis, Uveitis, Crohn’s disease and Children Crohn’s disease; Hanbetac, Bevacizumab injection, which treats metastatic Colorectal, recurrent glioblastoma, epithelial ovarian cancer and others and Hans-Shape, Slulizumab injection, for microsatellite high instability (MSI-H) solid tumors, squamous non-small cell lung cancer (sqNSCLC). Henlius is headquartered in Shanghai, China.
For a complete picture of Rituximab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
